Sahakyan Y, et al. - Individuals who acquired hepatitis C virus (HCV) through blood products between January 1986 and July 1990 were granted support by the Federal Government of Canada via establishing a $1.1 billion compensation program. Researchers here investigated the largest posttransfusion cohort in the literature (n = 4,550) followed for over 15 years from 2000 to 2016 for its morbidity and mortality. Relative to the Canadian general population, this cohort had markedly higher all-cause mortality rates. The posttransfusion cohort showed an almost double risk of death compared with that of the Canadian general population. HCV-related mortality was also greater relative to other HCV cohorts. This supports making continued efforts to recognize and manage posttransfusion HCV.